Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation

PURPOSE: Patients with EGFR-mutant lung adenocarcinoma develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) after a median of 10–16 months. In half of these cases a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Oxnard, Geoffrey R., Arcila, Maria E., Sima, Camelia S., Riely, Gregory J., Chmielecki, Juliann, Kris, Mark G., Pao, William, Ladanyi, Marc, Miller, Vincent A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3060283/
https://ncbi.nlm.nih.gov/pubmed/21135146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2692
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares